González-Martín Julià, García-García José María, Anibarro Luis, Vidal Rafael, Esteban Jaime, Blanquer Rafael, Moreno Santiago, Ruiz-Manzano Juan
Servei de Microbiologia, Institut Clínic de Diagnòstic Biomèdic (CDB), Hospital Clínic, Institut Clínic de Diagnòstic Biomèdic August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, España.
Arch Bronconeumol. 2010 May;46(5):255-74. doi: 10.1016/j.arbres.2010.02.010. Epub 2010 May 5.
Pulmonary TB should be suspected in patients with respiratory symptoms longer than 2-3 weeks. Immunosuppression may modify clinical and radiological presentation. Chest X-ray shows very suggestive, albeit sometimes atypical, signs of TB. Complex radiological tests (CT scan, MR) are more useful in extrapulmonary TB. At least 3 serial representative samples of the clinical location are used for diagnosis whenever possible. Bacilloscopy and liquid medium cultures are indicated in all cases. Genetic amplification techniques are coadjuvant in moderate or high TB suspicion. Administration of isoniazid, rifampicin, ethambutol and pyrazinamide (HREZ) for 2 months and HR for 4 additional months is recommended in new cases of TB, except in cases of meningitis in which treatment should continue for up to 12 months and up to 9 months in spinal TB with neurological involvement, and in silicosis. Appropriate adjustments with antiretroviral treatment should be made in HIV patients. Combined therapy is recommended to avoid development of resistance. An antibiogram to first line drugs should be performed in all the initial isolations of new patients. Treatment control is one of the most important activities in TB management. The Tuberculin Skin Test (TST) is positive in TB infection when >or=5mm, and Interferon-Gamma Release Assays (IGRA) are recommended in combination with TT. The standard treatment schedule for infection is 6 months with isoniazid. In pulmonary TB, respiratory isolation is applied for 3 weeks or until 3 negative bacilloscopy samples are obtained.
出现呼吸道症状超过2 - 3周的患者应怀疑患有肺结核。免疫抑制可能会改变临床和放射学表现。胸部X光显示出非常典型的,尽管有时是非典型的肺结核迹象。复杂的放射学检查(CT扫描、磁共振成像)在肺外结核中更有用。只要有可能,至少采集3份临床病变部位的连续代表性样本用于诊断。所有病例均需进行涂片镜检和液体培养基培养。在中度或高度怀疑肺结核时,基因扩增技术作为辅助手段。对于新诊断的肺结核病例,推荐使用异烟肼、利福平、乙胺丁醇和吡嗪酰胺(HREZ)联合治疗2个月,之后继续使用HR联合治疗4个月,但结核性脑膜炎病例治疗应持续12个月,合并神经系统受累的脊柱结核病例治疗应持续9个月,矽肺患者也应如此。对于HIV患者,应适当调整抗逆转录病毒治疗方案。建议联合治疗以避免耐药性的产生。所有新患者初次分离出结核杆菌时均应进行一线药物药敏试验。治疗监测是结核病管理中最重要的工作之一。结核菌素皮肤试验(TST)硬结直径≥5mm为结核感染阳性,推荐将干扰素-γ释放试验(IGRA)与TST联合使用。结核感染的标准治疗方案是使用异烟肼治疗6个月。对于肺结核患者,应进行3周的呼吸道隔离,或直至获得3份痰涂片阴性样本。